Overview

Inflammatory Disease Market is poised to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027.

The body generally reacts to foreign substance by generating heat which helps in the elimination of necrotic, dead cells. But in some cases, the body reacts to the activities of its own cells thus triggering inflammation resulting into diseases like multiple sclerosis, asthma, COPD, etc.  

FutureWise Market Research has instantiated a report that provides an intricate analysis of Inflammatory Disease Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Inflammatory Disease Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Inflammatory Disease Market:

• AstraZeneca
• Merck & Co. Inc.
• GlaxoSmithKline plc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• Sanofi
• Enlivex Therapeutics Ltd.
• Gilead Sciences Inc
• Immune Pharmaceuticals Inc.
• LG Chem
• Mitsubishi Tanabe Pharma Corporation
• Takeda Pharmaceutical Company Limited
• Celtaxsys
• Pharmaxis Ltd

(Note: The list of the major players will be updated with the latest market scenario and trends)

Inflammatory Disease Market Segmentation:

By Type of Disease

• Respiratory diseases
• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Heart Disease
• Multiple sclerosis
• Psoriasis
• Inflammatory bowel disease
• Bone Disease
• Rheumatoid Arthritis
• Osteoarthritis
• Others

By Drug Class

• Anti-inflammatory Biologics
• Non-Steroidal Anti-inflammatory drugs
• Corticosteroids
• Others

By End User

• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores
• Online Pharmacy

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Inflammatory Disease Market By Type of Disease, By Drug Class and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific and rest of the world
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
       1.1 Objectives of the Study 
       1.2 Market Definition 
       1.3 Market Scope 
               1.3.1 Years Considered for the Study
               1.3.2 Market Covered
       1.4 Currency 
       1.5 Limitations 
       1.6 Stakeholders 
2.  Research Methodology 
       2.1 Research Data 
         2.1.1 Secondary Data
                 2.1.1.1 Key Data from Secondary Sources
         2.1.2 Primary Data
                 2.1.2.1 Key Data from Primary Sources
       2.2 Market Size Estimation 
       2.3 Market Breakdown and Data Triangulation 
       2.4 Assumptions for the Study  
3. Executive Summary
       3.1 Market Outlook
       3.2 Segment Outlook
       3.3 Competitive Insights
4. Global Inflammatory Disease Market Variables, Trends & Scope
       4.1. Market Lineage Outlook
       4.2. Penetration and Growth Prospect Mapping
       4.3. Industry Value Chain Analysis
       4.4. Cost Analysis Breakdown
       4.5. Technology Overview
       4.6. Regulatory Framework
                 4.6.1. Reimbursement Framework
                 4.6.2. Standards and Compliances
5. Market Overview
       5.1. Market Dynamics
                  5.1.1. Market Driver Analysis
                            5.1.1.1. Increasing focus of Inflammatory Disease Companies on Brand Protection
                            5.1.1.2. Untapped Opportunities in Emerging Regions
                  5.1.2. Market Restraint Analysis
                            5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
                  5.1.3. Industry Challenges
                            5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Inflammatory Disease Market Analysis Tools
        6.1. Industry Analysis - Porter’s
               6.1.1. Supplier Power
               6.1.2. Buyer Power
               6.1.3. Substitution Threat
               6.1.4. Threat from New Entrants
               6.1.5. Competitive Rivalry
       6.2. Pestel Analysis
               6.2.1. Political Landscape
               6.2.2. Environmental Landscape
               6.2.3. Social Landscape
               6.2.4. Technology Landscape
               6.2.5. Legal Landscape
       6.3. Major Deals And Strategic Alliances Analysis
                6.3.1. Joint Ventures
                6.3.2. Mergers and Acquisitions
                6.3.3. Licensing and Partnership
                6.3.4. Technology Collaborations
                6.3.5. Strategic Divestments
       6.4. Market Entry Strategies
       6.5. Case Studies
7. Global Inflammatory Disease Market, By Type of Disease Historical Analysis and Forecast 2020-2027 (USD Million)
       7.1. Respiratory diseases
               7.1.1. Asthma
               7.1.2. Chronic obstructive pulmonary disease (COPD)
       7.2. Heart Disease 
       7.3. Multiple sclerosis
       7.4. Psoriasis
       7.5. Inflammatory bowel disease
       7.6. Bone Disease
             7.6.1. Rheumatoid Arthritis
             7.6.2. Osteoarthritis
       7.7. Others 
8. Global Inflammatory Disease Market, By Drug Class Historical Analysis and Forecast 2020-2027 (USD Million)
       8.1. Anti-inflammatory Biologics
       8.2. Non-Steroidal Anti-inflammatory drugs
       8.3. Corticosteroids
       8.4. Others
9. Global Inflammatory Disease Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
       9.1. Hospital Pharmacy
       9.2. Retail Pharmacy       
       9.3. Drug Stores
       9.4. Online Pharmacy
10.  North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       10.1. Introduction
       10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            10.2.1. U.S.A
            10.2.2. Canada
            10.2.3. Mexico
       10.3. Market Size (USD Million) Forecast for North America 2020-2027
11. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       11.1. Introduction
       11.2. Regional Market Trends
       11.3. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            11.3.1. Brazil
            11.3.2. Venezuela
            11.3.3. Argentina
            11.3.4. Rest of Latin America
       11.4. Market Size (USD Million) Forecast for Latin America 2020-2027
12. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       12.1. Introduction
       12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
            12.2.1. Germany
            12.2.2. U.K
            12.2.3. France
            12.2.4. Italy
            12.2.5. Spain
            12.2.6. Russia
            12.2.7. Poland
            12.2.8. Switzerland
            12.2.9. Rest of Western Europe
13. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       13.1. Introduction
       13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
             13.2.1. Japan
             13.2.2. China
             13.2.3. Singapore
             13.2.4. India
             13.2.5. Australia and New Zealand
             13.2.6. ASEAN
             13.2.7. South Korea
             13.2.8. Rest of Asia Pacific
       13.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
14. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
       14.1. Introduction
       14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
             14.2.1. Saudi Arabia
             14.2.2. UAE
             14.2.3. South Africa
             14.2.4. Egypt
       14.3. Market Size (USD Million) Forecast for MEA 2020-2027
15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Technology Portfolio, Financial Layouts)
       15.1. AstraZeneca
                15.1.1. Company Overview
                15.1.2. Product Portfolio
                15.1.3. SWOT Analysis
                15.1.4. Financial Overview
                15.1.5. Strategic Overview
       15.2. Merck & Co. Inc.
                15.2.1. Company Overview
                15.2.2. Product Portfolio
                15.2.3. SWOT Analysis
                15.2.4. Financial Overview
                15.2.5. Strategic Overview
       15.3. GlaxoSmithKline plc.
                15.3.1. Company Overview
                15.3.2. Product Portfolio
                15.3.3. SWOT Analysis
                15.3.4. Financial Overview
                15.3.5. Strategic Overview
       15.4. Bristol-Myers Squibb Company
                15.4.1. Company Overview
                15.4.2. Product Portfolio
                15.4.3. SWOT Analysis
                15.4.4. Financial Overview
                15.4.5. Strategic Overview
       15.5. F. Hoffmann-La Roche Ltd
                15.5.1. Company Overview
                15.5.2. Product Portfolio
                15.5.3. SWOT Analysis
                15.5.4. Financial Overview
                15.5.5. Strategic Overview
       15.6. Eli Lilly and Company
                15.6.1. Company Overview
                15.6.2. Product Portfolio
                15.6.3. SWOT Analysis
                15.6.4. Financial Overview
                15.6.5. Strategic Overview
       15.7. Sanofi
                15.7.1. Company Overview
                15.7.2. Product Portfolio
                15.7.3. SWOT Analysis
                15.7.4. Financial Overview
                15.7.5. Strategic Overview
       15.8. Enlivex Therapeutics Ltd.
                15.8.1. Company Overview
                15.8.2. Product Portfolio
                15.8.3. SWOT Analysis
                15.8.4. Financial Overview
                15.8.5. Strategic Overview
       15.9. Gilead Sciences Inc
                15.9.1. Company Overview
                15.9.2. Product Portfolio
                15.9.3. SWOT Analysis
                15.9.4. Financial Overview
                15.9.5. Strategic Overview
       15.10. Immune Pharmaceuticals Inc.
                15.10.1. Company Overview
                15.10.2. Product Portfolio
                15.10.3. SWOT Analysis
                15.10.4. Financial Overview
                15.10.5. Strategic Overview
       15.11. LG Chem
                15.11.1. Company Overview
                15.11.2. Product Portfolio
                15.11.3. SWOT Analysis
                15.11.4. Financial Overview
                15.11.5. Strategic Overview
       15.12. Mitsubishi Tanabe Pharma Corporation
                15.12.1. Company Overview
                15.12.2. Product Portfolio
                15.12.3. SWOT Analysis
                15.12.4. Financial Overview
                15.12.5. Strategic Overview
       15.13. Takeda Pharmaceutical Company Limited
                15.13.1. Company Overview
                15.13.2. Product Portfolio
                15.13.3. SWOT Analysis
                15.13.4. Financial Overview
                15.13.5. Strategic Overview
       15.14. Celtaxsys
                15.14.1. Company Overview
                15.14.2. Product Portfolio
                15.14.3. SWOT Analysis
                15.14.4. Financial Overview
                15.14.5. Strategic Overview
       15.15. Pharmaxis Ltd
                15.15.1. Company Overview
                15.15.2. Product Portfolio
                15.15.3. SWOT Analysis
                15.15.4. Financial Overview
                15.15.5. Strategic Overview
16. FutureWise SME key takeaway points for Client

Tables

Figures